The Jerusalem PostDiplomatic challenges from US, Europe, Iran, await Israel's next prime minister - analysisPunchEkiti APM candidate promises 100 federal jobsDaily MaverickBHEKISISA: Robots, polony and the long road to recovery from schizophreniaInquirer EntertainmentMarian Rivera took just 1 day’s pay for ‘Balota,’ donated the rest to crew, charityInquirerResigning never crossed Sara Duterte’s mind despite impeachment, says spoxThe South AfricanBrand-new Bafana star’s playing style compared with Doctor KhumaloZDF heuteAktuelle Pressemitteilungen des ZDFFootball ItaliaNapoli eye Chelsea winger Gittens in January swoopNHK 社会JIS不適合生コン製造などで認証取り消し 麻生コンクリート工業Wirtualna PolskaGibała po marszu: "Morderca nie osiągnął swojego celu"DeadlineITV News & Guardian Closer To Publishing Sexual Misconduct Allegations About British Star After Injunction Appeal Deadline Passed20 MinutenCS, UBS – und bald 1000 Wohnungen? Uetlihof steht vor Verkauf
The Daily Newsstand · Free, Always
Tuesday, November 10, 2026

New cancer drug prices down by over 96%: MRP rules, how to check medicine rates, what changes from November 9

Translate

The revised Maximum Retail Prices (MRP) of more than 1,000 anti-cancer formulations came into effect on Monday. The government also introduced some reform to help customers be aware about the prices of the cancer drugs.

New cancer drug prices down by over 96%: New MRP rules, how to check medicine rates, what changes from November 9
New cancer drug prices down by over 96%: New MRP rules, how to check medicine rates, what changes from November 9

In a major relief to patients, the government announced on Monday that the Maximum Retail Prices (MRP) of anti-cancer medicines were "reduced by up to 96.45%."

The revised Maximum Retail Prices (MRP) of more than 1,000 anti-cancer formulations came into effect on Monday, a move projected to save consumers an estimated ₹3,540.38 crore annually, according to an official release.

The Department of Pharmaceuticals said the National Pharmaceutical Pricing Authority (NPPA) capped trade margins on the MRP of 137 anti-cancer drugs.

Out of the 137 identified anti-cancer drugs, 10-15 are yet to be launched in India. "However, Trade Margin Rationalisation (TMR) will be applicable on these drugs also as and when they are launched," the government said in the statement.

As of November 7, as many as 76 pharmaceutical companies had reported revised MRP for 1225 anti-cancer formulations, covering 121 drugs, the department said.

The reduction in the MRP of 1031 formulations of anti-cancer medicines was reported, with 600 brands reporting above 50 percent reduction and the highest reduction being 96.45 percent.

Besides the reduction in the MRP, here are some more changes that customers will see:

1. The revised MRP will be printed on the pack and will apply in every pharmacy and hospital, from November 9.

2. One can check the price of the cancer on the Pharma Sahi Daam app. No pharmacy or chemist can charge more than the price listed on the app or printed on the medication pack.

3. If charged more, the person can complain to NPPA via the Pharma Sahi Daam app/ portal or call 1800-111-255

How to check medicine rates online before purchasing?

One can verify printed pack prices or search for official rates on the Pharma Sahi Daam Mobile Application or on the NPPA official website (nppa.gov.in).

Every retailer, dealer, hospital and institution is required to prominently display the revised MRP list of anti-cancer medicines on their websites and in their premises.

"As per the NPPA notification, State Drug Controllers will monitor compliance by manufacturers, dealers, Hospitals and Medical Institutions," the department said in its statement.

"Consumers can check the applicable prices through the Pharma Sahi Daam mobile application and the NPPA website (www.nppa.gov.in) and report any non-compliance or violation of revised prices to the authority," it added.

Is pharmacy/chemist charging you more for a medicine? Here's how to file complaint when charges more

Complaints can be submitted through the following channels:

Email: monitoring-nppa[at]gov[dot]in

Helpline: 1800-11-1255

Post: Deputy Director, Monitoring, NPPA, 3rd Floor, YMCA Cultural Centre Building, 1 Jai Singh Marg, New Delhi – 110001.

About the Author

Akriti Anand is a Deputy Chief Content Producer at LiveMint. She is a digital journalist with more than six years in the news industry.<br><br> In her current role, she covers both national and international politics, and also keeps a close watch on the latest trends in science and space exploration. <br><br> Akriti joined the LiveMint team in October 2023. Before this, she built a strong career at other major media houses. She worked as a senior sub-editor at India Today. Later, she moved to CNBCTV-18. There, she covered high-pressure topics like breaking news and major elections. She spent much of her time analysing Parliament bills and complex political debates. She is also a skilled editor who knows how to polish a story for a digital audience. <br><br> One of her career highlights happened at CNBCTV-18. She made her first television debut during the Chandrayaan-3 mission. She also provided special on-air coverage for the Karnataka Elections. <br><br> When she is not busy with breaking news, Akriti loves to write explainers and interview experts on a wide range of issues. She also enjoys making complex space missions easy for everyone to understand. <br><br> Her education helps her tackle these diverse subjects. She holds a BA in English Literature, a Postgraduate Diploma in Mass Communication, and a Master’s degree in Development Studies. She is currently expanding her knowledge in climate journalism.<br><br> Connect with Akriti here<br> LinkedIn: <a href="https://www.linkedin.com/in/akriti-anand-868285199">https://www.linkedin.com/in/akriti-anand-868285199</a><br> Twitter/X: <a href="https://x.com/AkritiAnand7">https://x.com/AkritiAnand7</a><br> Email: akriti.anand@htdigital.in

View the original on Mint →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.